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The Role of Industry in the Development of Biomedical Technologyt 
Raymond H. Kahn, PhD' 
The world is undergoing a biological revolution that has 
made unparalleled demands on the American health care 
system. This demand for health care and its escalating costs 
provide abundant Incentives for reducing the cost through 
better technology. Recent developments in medical tech-
nology include the CAT scanner, nuclear magnetic reso-
nance (NMR), as well as new advances in prosthetic 
devices. Most biomedical research and development takes 
place at not-for-profit institutions, such as universities, 
hospitals, and private foundations, much of it supported by 
federal funding from such sources as the National Institutes 
of Health. But, today, the institutions are In danger of major 
cutbacks in funding at a time when inflation has already 
endangered the resources available for biomedical re-
search. One potential solution to this problem Is to encour-
age a better relationship between industry and the research 
community; in a period when federal support is obviously 
leveling off, industry can provide the vital margin while 
simultaneously encouraging a continued federal 
commitment. 
Unfortunately, the objectives of research do not parallel 
those of industry. Scholarship traditionally has been de-
voted to the transfer of information by publication, while 
industry responds to the proprietary needs ofa corporation 
and reflects a commitment to the profit motive. Clearly, any 
"marriage" of industry with the scientific research commu-
nity as a cooperative venture will require some innovative 
thinking on the part of both. 
W h i l e only recently appreciated, the world is undergo-
ing a biological revolution, a revolution which wi l l rival the 
industrial revolution. The impact of this upheaval wi l l far 
exceed the consequences of industrialization, for it wi l l 
affect not only the quality of life but life itself. Until now, 
the U.S. has been the unparal leled leader in the life 
sciences, as a direct result of the public support initiated by 
the National Institutes of Health (NIH) 30 years ago. In 
1950, less than 0.06% ofour Gross National Product (GNP) 
was invested in research and development. Largely fostered 
by Congress, that support has increased more than five-fold 
so that it now stands at 0.31% of the GNP (1). 
Increased Costs of Health Care 
When compared to the expenditure for health care, which 
is over $200 billion annually (2), this nation's commitment 
to research and development in the life sciences pales into 
insignificance. This cost is a 16-fold increase overthe same 
30-year period and now accounts for more than 9% ofour 
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GNP (3). This sharp increase in our health care cost is a 
function of a number of factors (4), including a significant 
population increase that has been exacerbated by a shift in 
aging (3). Today, 11% ofour citizens are over 65 years of 
age, and this percentage is increasing with time so that by 
the year 2000 about one fifth of the nation wil l be over 65. 
Another factor which affects health care costs is pre-paid 
health insurance and general affluence, both resulting in 
greater public expectation and demands on the health care 
system. Probably the most important factor is that health 
care is labor intensive. While the number of support per-
sonnel varies from hospital to hospital, depending on 
whether it is a community hospital or a tertiary care center 
such as Henry Ford Hospital, two to three employees are 
required for each patient bed, excluding physicians and 
residents. It is noteworthy that health care is the only 
industry that does not support its own research and 
development. 
This demand for health care and the explosive costs of such 
care provide abundant incentives for reducing the cost 
through better technology. Until quite recently, the transfer 
of information from the research laboratory to the bedside 
was slow and frequently undirected. But the pace from 
invention to practice hasquickened as adirect result of the 
commercialization of a few highly visible technical ad-
vances such as genetic research (4), aided by a large force 
of scientists trained with federal grants. The result is an 
explosion of laboratory innovation fostered by sophisti-
cated instrumentation. Monthly, morethan 25,000journals 
are published in biology and medicine; the average scien-
tist must scan titles retrieved by computer simply to keep 
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up in the field. Clearly, technology has affected major 
changes in the cost of health care (5). 
Human suffering notwithstanding, consider for a moment 
the financial impact of the polio vaccine. Developed over 
a number of years, this vaccine became medically ac-
cepted and widely distributed in 1955. Without it, over half 
a million people would have contracted the disease in the 
past 25 years. Of those, 8% would have died, 24% would 
have been totally disabled, and the rest either partially or 
mildly affected. Based on these rough estimates of dis-
ability and projecting for inflationary increases, it would 
have cost the U.S. over $100 billion in medical charges and 
loss of income. Since the total cost of the vaccine and the 
field trials was $41 mill ion, the savings to date are 200,000 
times the cost. Comparable figures can be cited for the 
incidence of tuberculosis, measles, or whooping cough. 
However, success with infectious diseases has not been 
universal, and the current cost of gonorrhea and hepatitis 
can only be surmised. Since heart disease remains by far 
the number one killer, with cancer not far behind, it is clear 
that there are numerous opportunities for an expanding 
and cost-effective market. 
Recent Advances in Medical Technology 
Diagnostic devices 
To look at what opportunities do exist, it seems worthwhile 
to briefly comment on a few of the advances that have 
occurred in recent years, emphasizing that many of these 
were not even conceived 10 years ago. A classic example 
of new technology is the computerized axial tomography 
(CAT) scanner, a machine with the capacity to synthesize 
normally uniplanar x-rays into multiplanar views of the 
body. This diagnostic tool is only now being appreciated 
and made available. Somewhat less well known but with a 
great deal of potential is the use of ultrasound waves to 
generate structural images. Sonography was undertaken as 
a direct outcome of sonar developed during World War II. 
Although its resolving power needs significant improve-
ment, the capability it provides to view the fetus in utero 
noninvasively or to see heart valves in action portends 
important breakthroughs. One that is already a reality, 
albeit primitive, isthe Positron Emission Tomography (PET) 
scanner, which visualizes injected radioactive agents as 
they localize within the body. Once again, this instrument 
depends on the computer to recreate a two-dimensional 
picture, yielding a cross-sectional view of the head or body. 
It is important to recognize that the PET scanner responds 
to the functional status of the patient, rather than depend-
ing solely on the structural changes visualized by ultra-
sound on the CAT scanner. 
Among other diagnostic devices that we can envision as 
both feasible and useful to the health care industry wi l l be a 
device that can monitor a whole host of metabolic param-
eters noninvasively, (e.g., topical magnetic resonance). It 
would be extremely useful to be able to assess blood flow 
and pressure continuously, rather than to rely on intermit-
tent readings taken in the doctor's office. As another exam-
ple, our current understanding of the chemistry of blood 
clotting is truly embryonic. Theoretically, blood chemistry 
should be a good indicator of clotting tendencies and 
should therefore be able to predict such illnesses as a stroke 
or heart attack. These new health parameters wou ld 
provide a better understanding of the ranges and conse-
quences of bodily functions and would most likely re-
define normal values. Similarly, more sophisticated tech-
niques for analyzing cell and tissue structure routinely and 
automatically would reduce the cost of diagnosis. Image 
analysis has that potential, for it quantifies any photograph 
or visual image into a digitized pattern. Conceivably, auto-
matic scanning of cells such as the Pap smear or human 
chromosomes by image analysis to distinguish and predict 
potential congenital defects would not only reduce costs 
but could expand our current expertise. 
Hybridoma techniques 
Any discussion of diagnostic possibilities must highlight the 
current excitement over hybridomas. Techniques to foster 
the fusion of cells in tissue culture have been recently 
discovered. Consequently, cells with the ability to make 
specific antibodies can be isolated after fusion has taken 
place with a myeloma cell as a hybrid. As a malignant cell, 
the myeloma cell can propagate continuously. Thus, this 
new technology provides forthe continuous propagation of 
specific antibodies. 
It follows that we shall soon have the ability to detect 
markers on diagnostically important cell types and, as we 
shall see, in the near future generate specific human anti-
bod ies on a production basis. Combined with image analy-
sis, new horizons in diagnosis can be projected. However, 
the technology for fabricating, distributing, and marketing 
antibodies is still to be defined. Finally, I would note that a 
series of laboratories are actively pursuing chemical factors 
with the potential to diagnose selected cancers. These 
include alphafetoprotein, carcino-embryonic antigen 
(CEA), and others. 
Half technology versus full technology 
In any discussion of potential changes with respect to 
therapy, it is important to distinguish between therapeutic 
techniques that are "substitutive", or act as replacements, 
and those that truly cure the disease. Lewis Thomas in his 
recent book. Lives of the Cell, compares these two by 
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referring to the former as "half technology", while defining 
therapies which remove the cause of a disease as "ful l 
technology". A heart transplant or any prosthesis that 
mimicks the heart, such as the left ventricular assist devices 
(LVAD), are not directly addressing the problem. An indi-
vidual may need a replacement heart because the coronary 
vessels are occluded or portions of the heart muscle are 
destroyed beyond repair. While the transplanted heart or 
the prosthetic device solves the person's immediate need, 
it clearly has not solved the fundamental problem, namely, 
the changes in the structure and function of the blood 
vessels or heart musculature. As Thomas points out, half 
technology, e.g., kidney translants, is glamorous and ex-
pensive. On the other hand, full technology is far less 
expensive and quickly becomes mundane. Consider how 
readily we accept insulin therapy, antibiotics, or the Salk/ 
Sabin vaccine. Half technology for the treatment of pol-
iomylelitis in contemporary terms would have yielded a 
computerized iron lung. 
With respect to curative therapy, much interest has evolved 
in the last few years for procedures to enhance radiation 
therapy that wi l l selectively destroy cancer cells. One 
concept that has significant potential is the technique of 
hyperthermia, which raises the temperature in a specified 
region of the body and permits a lower dose of radiation to 
be effective. A second technique combines fiberoptics with 
laser light sources to bring specific wave lengths into play 
in order to modify the chemical structure of materials 
selectively placed at the site of a cancer or lesion. As noted 
previously, the availability of specific antibodies derived 
from hybridomas which would bind with foreign protein, 
be it an infectious agent such as a virus or a toxic chemical 
such as bee venom or PBB, would also provide a specific 
cure to the problem. Thus, within the foreseeable future, 
specific antibodies to provide passive immunity and/or 
generate unique vaccines against hepatitis, herpes, and 
other viral or foreign proteins wil l become feasible. Graft 
protection for the transplanted kidney, heart, or other 
organs as well as tumor rejection can be anticipated as 
well. In this same category, current research has identified a 
series of materials that appear to be specifically antiviral, 
most notably a substance called interferon. 
curative therapy. While the problem of the traumatized 
knee or hip has been addressed frequently over the years, 
the perfect solution has yet to be defined. It is especially 
difficult to maintain prostheses over a long period of time 
in a fixed structural relationship with bone. While cosmet-
ically acceptable replacement limbs for the amputee are 
available, they still lack the needed mobility. Conceivably, 
this established technology can be combined with micro-
electronics and ultimately with sensors to nerve endings to 
produce highly sophisticated systems of limb control. In 
this connection, the ability to transplant muscle and even 
stimulate new muscle growth has real promise. 
Problems which are actively being addressed include re-
finements of materials that are compatible with living 
tissue, including biocompatible glues, plastics, ceramics, 
and carbons. Devices that wi l l transmit energy across the 
skin to power pacemakers and obviate invasive surgery; 
mechanisms to process neural information and transmit 
that informat ion to the brain enabl ing feedback; re-
calcification of teeth; artificial hearing and visual pros-
theses— all are in the earliest stages of development. 
Solutions to these biological problems wi l l undoubtedly be 
the impetus to new directions in technology. As a scientist, 
I have a real sense of excitement at being at the frontiers of 
discovery. But there are frustrations as well . 
Risks for Biomedical Research 
The not-for-profit research institutions, such as universities, 
hospitals, and foundations, are responsible for much of the 
biomedical research and development in the U.S., since 
scholarship is a prime objective and an integral partof their 
programs. In a very real sense, this country's leadership in 
biomedical technology, as in many other fields, depends 
on the survival of these institutions. This leadership is best 
evidenced by the repeated recognition the world has given 
to American scientists, notthe least of which has been the 
frequency with which Americans have been awarded the 
Nobel Prize. Moreover, the research created at such re-
search institutions is of the highest quality and has cost 
relatively little. In the best fiscal sense, American research 
has been a bargain! 
Prosthetic devices 
With respect to prosthetics, much can be reported, and I 
wi l l necessarily limit my discussion to a few examples. One 
such instance is the development of new, nonthrom-
bogenic blood vessels by lining fabricated tubes with living 
cells derived from the potential recipient. This technique 
would enable the surgeon to tailor-make vessels of any 
diameter or configuration. Obviously, there are other in-
stances of trauma or disease that wil l never respond to 
Loss of federal funding 
However, these research institutions are in trouble. As 
noted previously, until now the federal government has 
been largely responsible for the support of research and 
development and for the training of new scientists. In the 
last decade (1), NIH has significantly reduced its support of 
research in constant dollars, while at the same time many 
time-consuming and costly regulations have been pro-
mulgated. Currently, the nation is facing severe fiscal con-
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straints, and research and development are especially 
susceptible to cost-cutting as one of the few remaining so-
called "discretionary" expenditures. In an inflationary 
economy, biomedical research is especially vulnerable. 
Only 2% of the budget of the Department of Health and 
Human Services is currently attributable to research. Most 
ofthe Department's budget is "fixed entitlements" that are 
committed to supporting the Social Security system or 
required for Medicare and Medicaid through the Health 
Care Finance Administration (HCFA). The danger is that 
research institutions wil l be deprived of one of their major 
sources of support at a time when they are least able to 
cope. As you know, the state of Michigan is particularly 
susceptible to this loss as a reflection of our dependence on 
the automotive industry. With fiscal stringency, moreover, 
philanthropic support and/or state general funds have be-
come increasingly difficult to maintain. However, technol-
ogy cannot accept a hiatus in funding, for innovation is not 
something one can create, allow to die for lack of funding, 
and expect to resurrect without an extended delay and 
much pain. 
The "Marriage" of Research and Industry 
One potential solution is to promote a better relationship 
between industry and the research community (7). That 
relationship has to be assertively pursued by this commu-
nity as well as by industry and supported by venture capital 
(8). The catalytic effectof bringing together the counseling, 
peer review, legal expertise, marketing experience, and 
venture capital could foster many new and profitable 
industries. 
Unfortunately, the objectives of research do not parallel 
those of industry. Scholarship traditionally has been de-
voted to the transfer of information by publication. Industry, 
on the other hand, must respond to the proprietary needs of 
a corporation and reflect a commitment to the profit mo-
tive. Clearly, any "marriage" of industry with the scientific 
research community as a cooperative venture wil l require 
some innovative thinking on the part of both. At the outset, 
the not-for-profit institutions wil l have to more readily 
accept a more liberal attitude and recognize that consul-
tants and patents, aside from personal profit, represent a 
significant contribution to society. Moreover, scientists wil l 
have to accept that the free exchange of information may 
require a delay at least long enough to protect ideas and 
inventions by the patent process. For some reason, many 
individuals view this process as demeaning (9). In fact, 
patents are designed to facilitate the exchange of informa-
tion, and such reticence on the part of the scientists and 
scholars is surprising. For its part, industry must recognize 
the importance of excellence, objectivity, and impartiality 
to the researcher. The benefits would be the rapid diffusion 
of technology to society with financial returns to the inno-
vator, to the institution that provides the environment, and 
to industry. Whatever the mechanism, it lies within the 
power of the aforementioned to make this cooperative 
venture a reality. 
To make this marriage of science and industry work, we 
haveto be realistic. As Dr. Donald S. Frederickson, former 
NIH Director, warned in a recent address to the Royal 
College of London: "Much of the basic research on which 
profitable development depends cannot be supported by 
industry or any other private sources" (1). I would agree. 
Surely, industry cannot afford to support all basic research 
or provide the necessary clinical assessment of every pro-
spective device and therapeutic material. Nor can industry 
expect to compete with the current national investment of 
better than $3 billion in research. However, 1 would em-
phasize that if the expertise we have gained heretofore is to 
be sustained, then it is in the best interest of industry to 
support a continued national commitment to research and 
development. In a period when federal support is ob-
viously leveling off, industry can provide the vital margin 
while simultaneously encouraging a continued federal 
commitment. The recently passed law on patents provides 
research institutions with special privileges and wil l man-
date uniform regulations. Moreover, the current impetus to 
provide tax incentives for industrial investments to research 
institutions should further serve to encourage their 
cooperation. 
The future of health care is tied to the well-being of our 
research community, and both are important to all ele-
ments of our society. 
References 
1. Frederickson DS. Biomedical research in the 1980s. N Engl J Med 
1981;304(9):509-17. 
2. U.S. Department of Health, Education and Welfare, Health Resources 
Administration. 1976. Trends affecting U.S. health care system (DHEW 
publication no. (HRA) 76-14503). 
3. U.S. Department of Commerce, Bureau of the Census. 1979. Statistical 
Abstract of the United States. U.S. Government Printing Office. 
4. Anonymous. High technology, wave of the future or flash in the pan? 
Business Week 1980, Nov 10. 
5. Gibson w c The cost of not doing medical research. JAMA 1980; 
244:1817-19. 
6. Thomas L. The lives of the cel l : Notes of a biology watcher. New York: 
Viking Press, 1974. 
7. Prager DJ, Omenn CS. Research, innovation, and university-industry 
linkages. Science 1980;207:379-94. 
8. Brophy DJ. Finance, entrepreneurship, and economic development. 
Industrial Development Division, I.S.T. Ann Arbor: The University of 
Michigan, 1974. 
9. Anonymous. The colleges discover a profit in patents. Business Week 
1981, Jan 12. 
164 
